First Line TIP in Poor Prognosis TGCTs.
TIP in the 1st line treatment of GCTs patients with unfavorable decline of serum tumor markers after 1 cycle of the BEP regimen.TIP will be administered to the patient until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements.
Germ Cell Tumor
DRUG: Paclitaxel|DRUG: Ifosfamide|DRUG: Cisplatin
Complete response rate, according RECIST criteria version 1.1, 36 month
Response rate, response rate after chemotherapy, 36 month|Progression-free survival, expressed as median and as 12-weeks post-treatment initiation continuous progression-free survival rate, 36 month|Number of adverse events grade III and IV, 36 month|overall survival, Survival will be estimated from the registration date to the date of last follow-up or death. Patients will be followed at least 3 years., 36 months
Cycle 1: BEP regimen

Serum tumor markers at day 18-21:

â€¢Patients with an unfavorable pattern of tumor marker decrease after 1 cycle of BEP will receive 4 more cycles of TIP.

TIP regimen:

* Taxol 250 mg/ m2 iv on day 1
* Ifosfamid 1,2 g/ m2/ day iv x 5 days
* Cisplatin 20 mg/ m2/ day iv x 5 days One cycle of therapy consists of 22 days. Estimated duration of treatment: Until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements.